|
|
Article: Valeritas' SPAC Deal Gets $140M For Insulin Therapy.(Company overview)
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
West Coast Editor
With its approved h-Patch delivery system, Valeritas Inc. - soon to be majority owned by Paramount Acquisition Corp. - hopes to capture the burgeoning market for insulin that Type II diabetics find easy to use.
"We wanted to create some clever, differentiating tools to deliver molecules and go around the oral route," said Robert Gonnelli, who founded Westborough, Mass.-based BioValve Technologies Inc. in 1998, and spun out Valeritas about two weeks ago.
The h-Patch, recently the subject of 510(k) clearance from the FDA, drew the attention of Paramount, of New York, an affiliate of Paramount Biosciences, also of New York, which ...
Related newspaper, magazine, and journal articles:
|
|
Article: John Timberlake, Valeritas' Executive Vice President and ...
PR Newswire;
October 23, 2007 ;
700+ words
... ... N.J., Oct. 23 /PRNewswire/ -- Valeritas, LLC, a medical technology company ... Vice President and General Manager of Valeritas, LLC was awarded the distinguished Executive ... with diabetes. In his current role at Valeritas, he is focused on commercializing and ...
|
|